TEVA (Teva) Enterprise Value-to-Revenue Coefficient

Public company logo of Teva Pharmaceuticals (TEVA)

The EV/Sales multiple history demonstrates the position of Teva Pharmaceutical Industries (TEVA) as a generics leader relying on mass production and global demand. However, massive debt and ongoing litigation are constraining operational growth. The transition toward biosimilars and branded products is helping Teva Pharmaceutical Industries (TEVA) overcome price dumping. The value of 3403.84 determines the latest enterprise value to revenue metric, excluding debt.

Teva Pharmaceutical Industries Ltd. (TEVA): Company Value to Revenue from 11/23/2025 to 11/21/2026

Financial and market metric breakdowns for Teva Pharmaceuticals (TEVA)

- stock value and consensus price forecast:
- business market valuation indicators:
Initial company analysis:Teva Pharmaceutical Industries Ltd.
Mass-produced product of Teva

For Teva Pharmaceutical Industries (TEVA), burdened by debt obligations and litigation risks, this indicator becomes a critical filter for assessing the business's real value. The metric compares the enterprise value (EV), including debt, with annual revenue, eliminating the impact of capital structure on the result. Analysis of the EV/Sales valuation chart allows for the determination of whether the asset is overbought amid regulatory pressure and pricing competition in the generics sector.